3-Antigen Hepatitis B Vaccine Successfully Scales

VBI Vaccines Inc. today announced a business update and financial results for the March 31, 2024 quarter. The Company's innovative Hepatitis B vaccine (PreHevbrio®, PreHevbri®) has quickly gained global market access and produced measurable revenues.

PreHevbrio is the only 3-antigen hepatitis B vaccine, comprised of the three surface antigens of the hepatitis B virus.

"To date in 2024, our focus has centered around pipeline execution, expanding access and increased uptake of PreHevbrio in targeted market segments, and execution of strategic partnerships to drive opportunity for our portfolio assets, create shareholder value, and strengthen our balance sheet," said Jeff Baxter, VBI's President and CEO, in a press release on May 16, 2024.

PreHevbrio product revenue net increased 105% from Q1 2023, with $1.0 million earned in Q1 2024. During early 2024, PreHevbrio U.S. sales continue to demonstrate substantial growth over 2023, with over 80% of the 2023 full-year volume being sold in the first five months of 2024.

Furthermore, VBI partners with Valneva SE to make PreHevbri available in certain European countries. PreHevbri was launched in the UK, Sweden, Netherlands, and Belgium in 2023, and in early 2024, PreHevbri also became available in Denmark and Norway.